SCHEMBL3782735

SCHEMBL3782735

Fc1ccc(CNc2nc(Cl)nc3ccccc23)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 7/20 0.81
PDE5A O76074 4/20 0.81
MAPT P10636 3/20 0.71
KMT2A Q03164 3/20 0.71
LMNA P02545 3/20 0.71
MEN1 O00255 2/20 0.71
POLB P06746 2/20 0.60
USP1 O94782 2/20 0.60
WDR48 Q8TAF3 2/20 0.60
MAPK1 P28482 2/20 0.58
RAD52 P43351 1/20 0.57
GBA1 P04062 1/20 0.57
ATM Q13315 1/20 0.57
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
PKM P14618 1/20 0.56
UBE2N P61088 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
RCE1 Q9Y256 1/20 0.56
CYP1A2 P05177 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29388255 0.90 APP (1.00) APPPDE5AMAPTKMT2ALMNA
SCHEMBL3113122 0.90 APP (1.00) APPPDE5AMAPTKMT2ALMNA
SCHEMBL3106597 0.88 APP (0.85) APPPDE5AMAPTKMT2ALMNA
SCHEMBL4175973 0.88 CTNNB1 (0.72) APPPDE5AMAPTKMT2ALMNA
SCHEMBL3643055 0.86 PDE5A (0.58) APPPDE5AMAPTKMT2ALMNA
SCHEMBL3113251 0.86 APP (0.81) APPPDE5AMAPTKMT2ALMNA
SCHEMBL3121152 0.86 APP (0.81) APPPDE5AMAPTKMT2ALMNA
SCHEMBL4174731 0.85 CTNNB1 (0.75) CTNNB1TCF7L2
SCHEMBL13929497 0.85 APP (0.70) APPPDE5AMAPTKMT2ALMNA
SCHEMBL3638414 0.85 APP (0.74) APPPDE5AMAPTKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317607-A1 USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS INFECTIOUS DISEASE RESEARCH INSTITUTE (US) 2010-12-16 US disclosed
CN-101784276-A Use of compounds for the preparation of antituberculosis agents SUMMIT CORP PLC 2010-07-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317607-A1 USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS TPX2, DCXR, RRM2 APP 3840/4885PDE5A 2048/4885MAPT 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.